Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication

Factor VIII (FVIII) inhibitor formation is a major clinical concern during replacement therapy in patients with hemophilia A. Immune tolerance induction (ITI) is the only therapeutic approach to attempt inhibitor eradication and establishment of long-term immune tolerance to FVIII. Hemophilia Inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Helmut, Berg, Verena, Gangadharan, Bagirath, Bowen, Joel, LeBeau, Petra, Blatný, Jan, Male, Christoph, Radulescu, Vlad C., Diaz, Rosa, Mancuso, Maria Elisa, Brown, Deborah L., Reipert, Birgit M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Thrombosis and Hemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165197/
https://www.ncbi.nlm.nih.gov/pubmed/36074992
http://dx.doi.org/10.1182/bloodadvances.2022007267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165197/
https://www.ncbi.nlm.nih.gov/pubmed/36074992
http://dx.doi.org/10.1182/bloodadvances.2022007267

Ejemplares similares